While the interesting architecture and huge range of cultural attractions – not to mention the delicious food and craft drink scene – welcome you in, many of the best adventures to be had in Pittsburgh are outdoors. In the last reported quarter, SiBone delivered an earnings surprise of 26.83%.It’s one of the coolest spots in the US, but lovers of the great outdoors might also be tempted by 50,000km of waterways, 165 parks and the odd mountain to climb Placid test: a fine autumn day on one of Pittsburgh’s many lakes SIBN’s earnings beat estimates in all the trailing four quarters, the average surprise being 20.37%. Shares of the company have increased 31% in the past year compared with the industry’s rise of 1.9%. In the last reported quarter, it posted an earnings surprise of 55.56%.Įstimates for SiBone’s2023 loss have narrowed from $1.42 to $1.27 per share in the past 30 days. QTRX’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 30.39%. It currently carries a Zacks Rank #2 (Buy). Shares of the company have increased 167.5% in the past year against the industry’s decline of 1.7%. In the last reported quarter, it posted an earnings surprise of 38.16%.Įstimates for Quanterix’s 2023 loss per share have narrowed from $1.19 to 97 cents in the past 30 days. HAE’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 19.39%. Earnings estimates for Haemonetics have increased from $3.56 to $3.74 in 2023 and $3.96 to $4.07 in 2024 in the past 30 days. Haemonetics’ stock has risen 19.9% in the past year. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. Some better-ranked stocks in the broader medical space are Haemonetics HAE, Quanterix QTRX and SiBone SIBN. The Zacks Consensus Estimate for CRL’s 2023 revenues is pegged at $4.12 billion, suggesting a 3.6% rise from the year-ago reported number. The Zacks Consensus Estimate for its earnings has moved 1.6% north to $10.48 per share in the past 90 days. Estimate TrendĬharles River has been witnessing a positive estimate revision trend for 2023. For RMS, it has five main competitors: one is a government-funded, not-for-profit entity, one is privately held in Europe and three are privately held in the United States. The company primarily faces a broad range of competitors of different sizes and capabilities in its three business segments. The strengthening of the Euro and some other developed market currencies has constantly hampered the company’s performance in the international markets.Ĭompetitive Landscape: Charles River competes in the marketplace based on its therapeutic and scientific expertise in early-stage drug research, quality, reputation, flexibility, responsiveness, pricing, innovation and global capabilities. The current Zacks Consensus Estimate is pegged at $10.33 Downsidesįoreign Exchange Translation Impacts Sales: Foreign exchange is a significant headwind for Charles River due to a considerable percentage of its revenues coming from outside the United States. The Zacks Consensus Estimate for total revenues is pegged at $4.11 billion, indicating a 3.4% rise from 2022.Īdjusted earnings per share for 2023 are now expected in the range of $10.30-$10.90 ($9.90-$10.90). Organic revenue growth is expected to be 5.5-7.5% (5-7.5%). Upbeat Guidance: For 2023, CRL’s revenue growth is now expected in the band of 2.5-4.5% (from the earlier band of 2-4.5%) on a reported basis. The company is gaining from its extensive expertise in discovering preclinical candidates and in the design, execution and reporting of safety assessment studies for numerous compounds, including cell and gene therapies and small and large-molecule pharmaceuticals. At the beginning of 2023, the company was facing a dull performance in China.ĭSA Arm Continues to Thrive: Charles River is currently the largest provider of outsourced drug discovery, non-clinical development and regulated safety testing services worldwide. Global biopharmaceutical companies, small and midsized biotechs and academic and government accounts significantly contributed to the growth rate. Further, the company is showing strong growth within the end sourcing solutions business led by the CRADL operations or Charles River Accelerator and Development Labs initiative. RMS Business Rebounds: The RMS segment continues to benefit from broad-based growth in all geographic regions for small research models. The company has a long-term growth rate of 10.6% compared with the industry’s 13.5%. Operating as a full-service, early-stage contract research organization, Charles River has a market capitalization of $10.47 billion.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |